Public Release: 

Does patient-centered care in diabetes improve glycemic control and quality of life?

Mary Ann Liebert, Inc./Genetic Engineering News



Diabetes Technology & Therapeutics (DTT) is a monthly peer-reviewed journal that covers new technology and new products for the treatment, monitoring, diagnosis, and prevention of diabetes and its... view more

Credit: ©Mary Ann Liebert, Inc., publishers

New Rochelle, NY, October 4, 2016--A new study has found that while patient-centered care (PCC) was associated with significant improvements in both physical and mental quality of life and some aspects of diabetes self-management, it did not have a significant effect on glycemic control. PCC needs to expand more broadly throughout the healthcare system to have a meaningful impact on glycemic control, propose the authors of an article published in Diabetes Technology & Therapeutics (DTT), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the DTT website until November 4, 2016.

In the article "Patient-Centered Care, Glycemic Control, Diabetes Self-Care, and Quality of Life in Adults with Type 2 Diabetes" the researchers attribute The Affordable Care Act with a renewed emphasis on PCC and patients increasingly seeking information to help them take a more active role in disease management and treatment decisions.

Joni Williams, Rebekah Walker, Brittany Smalls, Rachel Hill, and Leonard Egede, Medical University of South Carolina and Ralph H. Johnson Department of Veterans Affairs Medical Center, Charleston, SC and Brigham and Women's Hospital, Boston, MA, report a significant relationship between PCC and several self-care behaviors including medication adherence, diet, exercise, and blood sugar testing.

"Patient engagement and self-care behaviors are essential in improving health outcomes for subjects with diabetes. Williams et al. report improved quality of life with patient-centered care in subjects with diabetes; however, their data did not support improvement in glucose control, which may be due to shorter follow up," says DTT Editor-in-Chief Satish Garg, MD, Professor of Medicine and Pediatrics at the University of Colorado Denver.


Research reported in this publication was supported by the National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health under Award Number K24KD093699-01. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

About the Journal

Diabetes Technology & Therapeutics (DTT) is a monthly peer-reviewed journal that covers new technology and new products for the treatment, monitoring, diagnosis, and prevention of diabetes and its complications. Led by Editor-in-Chief Satish Garg, MD, the Journal covers topics that include noninvasive glucose monitoring, implantable continuous glucose sensors, novel routes of insulin administration, genetic engineering, the artificial pancreas, measures of long-term control, computer applications for case management, telemedicine, the Internet, and new medications. Tables of contents and a free sample issue may be viewed on the Diabetes Technology & Therapeutics (DTT) website. DTT is the official journal of the Advanced Technologies & Treatments for Diabetes (ATTD) Conference.

About ATTD

The International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) presents top caliber scientific programs that have provided participants with cutting-edge research and analysis into the latest developments in diabetes-related technology. A unique and innovative conference, ATTD brings the world's leading researchers and clinicians together for a lively exchange of ideas and information related to the technology, treatment, and prevention of diabetes and related illnesses.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Thyroid, Metabolic Syndrome and Related Disorders, Journal of Aerosol Medicine and Pulmonary Drug Delivery, Childhood Obesity, and Population Health Management. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.